First important step towards better diagnostics for PDAC patients 💪
The first participant has been dosed with 68Ga-Trivehexin (RAD 301), a diagnostic radiopharmaceutical targeting αvβ6 integrin, for the detection of lesions in patients with Pancreatic Ductal Adenocarcinoma (PDAC): https://buff.ly/431zAmz The Phase I study of 9 participants is designed to assess the safety and dosimetry of RAD 301.
The first participant has been dosed with 68Ga-Trivehexin (RAD 301), a diagnostic radiopharmaceutical targeting αvβ6 integrin, for the detection of lesions in patients with Pancreatic Ductal Adenocarcinoma (PDAC): https://buff.ly/431zAmz The Phase I study of 9 participants is designed to assess the safety and dosimetry of RAD 301.
Did you know that ACE inhibitors, vital in treating cardiovascular disease, have roots in snake venom? Dive into the captivating journey from serpent fangs to pharmaceutical breakthroughs, revolutionizing cardiovascular treatment. Discover the untapped potential of venom-based drugs for future medical marvels. Read the article here: https://okt.to/fNz6MP #CardiovascularHealth #SnakeVenomResearch #MedicalInnovation #PharmaRoots #ReferenceStandards
Did you know that ACE inhibitors, vital in treating cardiovascular disease, have roots in snake venom? Dive into the captivating journey from serpent fangs to pharmaceutical breakthroughs, revolutionizing cardiovascular treatment. Discover the untapped potential of venom-based drugs for future medical marvels. Read our latest #PharmaRoots article here: https://okt.to/CtsqMR #CardiovascularHealth #SnakeVenomResearch #MedicalInnovation #PharmaRoots #ReferenceStandards
Did you know that ACE inhibitors, vital in treating cardiovascular disease, have roots in snake venom? Dive into the captivating journey from serpent fangs to pharmaceutical breakthroughs, revolutionizing cardiovascular treatment. Discover the untapped potential of venom-based drugs for future medical marvels. Read the article here: https://okt.to/zZbmOo #CardiovascularHealth #SnakeVenomResearch #MedicalInnovation #PharmaRoots #ReferenceStandards
#AACR24 BMS-986365, a Ligand Directed Androgen Receptor Degrader (AR LDD) #medicine First time disclosure from Shuichan Xu at New Drugs on the Horizon. Complete degradation! BMS-986365 (CC-94676) is an oral drug selectively targeting AR and induces effective and durable suppression of AR signaling, overcomes resistance to existing AR pathway inhibitors therapies and shows promising clinical activity in heavily pre-treated patients with mCRPC across wildtype, amplified and mutant AR status, highlighting this asset as the best-in-class AR-ligand directed degrader that may help overcome resistance to standard of care ARPIs in patients with mCRPC, a difficult-to-treat tumor type. #pharmaceuticals #healthcare Bristol Myers Squibb
$MNPR - The results in both show near complete elimination of the tumor after a single injection of the radiopharmaceutical agent. These studies demonstrate the potential of a MNPR-101 based radiopharmaceutical to provide a very meaningful clinical benefit to patients. https://lnkd.in/ethsdXBY
[Clinical Trials] Roche's phase 3 trial of Vabysmo reveals sustained retinal fluid dryness in CRVO and BRVO treatment https://lnkd.in/gC4pPu2g BridgeBio's Acoramidis Shows Positive Outcomes in Japan Phase III Trial for ATTR-CM https://lnkd.in/ga4qpnH9 [Deals] HUTCHMED announces Inmagene Biopharmaceuticals' exercise of licensing options for immunological drug candidates IMG-007 and IMG-004 https://lnkd.in/gvyDeund
VP Business Development | Cell & Gene Therapy Enthusiast | Liverpool FC Fan | @markflower@bsky.social
Breaking #CARTcellTherapy News: In an 11-0 vote the ODAC panel recommended the approval of a supplemental Biologics License Application (sBLA) for an updated indication - #MultipleMyeloma #Carvykti #CellTherapy #celltherapymanufacturing #apheresis
🔬We are thrilled to announce that Kiniksa Pharmaceuticals has commenced enrollment of the Phase 2b clinical trial of abiprubart in Sjögren’s Disease. With abiprubart, an investigational humanized anti-CD40 monoclonal antibody designed to inhibit the CD40-CD154 (CD40 ligand) interaction, Kiniksa aims to address this chronic autoimmune disorder that currently has no FDA-approved therapies. This marks a significant milestone in our mission to provide innovative treatments for patients with significant unmet medical needs. Learn more about today’s announcement in the press release here: https://lnkd.in/eVU4_AHb #Biopharma #ClinicalTrials #SjögrensDisease #EverySecondCounts #Kiniksa
PF-07817883 (Ibuzatrelvir): A Second-Generation Main Protease Inhibitor with Improved Metabolic Stability | https://lnkd.in/g5SVBnBb PF-07817883 (ibuzatrelvir) is an oral, second-generation SARS-CoV-2 Mpro inhibitor developed by Pfizer. These efforts follow the success of Pfizer's antiviral combination drug, Paxlovid, which was granted Emergency Use Authorization by the FDA for the treatment of COVID-19 just 17 months after its first synthesis in July 2020. PF-07817883 was granted Fast Track designation and recently completed a Ph. II clinical trial to evaluate its safety and efficacy in outpatient adults with COVID-19 symptoms. This article details the discovery strategy for PF-07817883, which includes addressing metabolic soft spots identified through MetID studies, recent clinical developments, reviewer commentary, and more. Full Article: https://lnkd.in/g5SVBnBb
